Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer.

Androgen deprivation therapy (ADT) for prostate cancer is associated with adverse effects, such as obesity and metabolic syndrome, which increase cardiovascular risk, the most common cause of non-cancer mortality in men diagnosed with prostate cancer. The Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) was created to determine the feasibility of conducing a comprehensive lifestyle modification intervention in men on ADT for prostate cancer and determine its early efficacy in reducing obesity and metabolic syndrome.

A single-arm, open-label clinical trial was conducted by recruiting 31 men diagnosed with prostate cancer and exposed to ADT within the last 5 years. A multicomponent lifestyle modification program was delivered weekly for 16 weeks by a trained health coach. This was followed by 8 weeks of passive follow-up resulting in a total trial duration of 24 weeks. Feasibility was determined by calculating study recruitment, retention, and adherence rates. Weight and components of metabolic syndrome (waist circumference, triglycerides (TG), high-density lipoprotein (HDL), serum glucose, and blood pressure (BP)) were measured at baseline, 12, and 24 weeks.

Recruitment, retention, and adherence rates were 47.1%, 90.3%, and 100%, respectively. Statistically significant improvements were noted between baseline and end of study measurements for weight (206.3 vs. 191.3 lbs, p < 0.001), waist (41.3 vs. 38.8 inches, p < 0.001), systolic BP (144.1 vs. 133.4 mm of Hg, p = 0.014), diastolic BP (83.3 vs. 76.2 mm of Hg, p = 0.0056), TG (146.0 vs. 113.8 mg/dl, p = 0.022), HDL (51.1 vs. 55.0 mg/dl, p = 0.012), and serum glucose (114.0 vs. 103.2 mg/dl, p = 0.013).

CLIPP demonstrates feasibility and early efficacy of a multicomponent lifestyle modification intervention toward addressing obesity as well as components of metabolic syndrome in men on ADT for prostate cancer. This study provides strong preliminary data to develop future clinical trials in this population.

Prostate cancer and prostatic diseases. 2021 Mar 25 [Epub ahead of print]

A M Algotar, C H Hsu, H-H Chow, S T Dougherty, H M Babiker, D G Marrero, I Abraham, R Kumar, J A Ligibel, K S Courneya, T E Smith, P A Jones, J N Lopez, G Niemiro, S Ramakumar, R D Hoy, C Mack, C A Thomson

Department of Family and Community Medicine, University of Arizona, Tucson, AZ, USA. ., The University of Arizona Cancer Center, Tucson, AZ, USA., Department of Health Promotion Science, Mel and Enid College of Public Health, University of Arizona, Tucson, AZ, USA., Department of Family and Community Medicine, University of Arizona, Tucson, AZ, USA., Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada., Department of Epidemiology and Biostatistics, Mel and Enid College of Public Health, University of Arizona, Tucson, AZ, USA., Department of Pediatrics, University of Arizona, Tucson, AZ, USA., Arizona Institute of Urology, Tucson, AZ, USA., Arizona Oncology, Tucson, AZ, USA.